nVerses Capital’s Emergent Biosolutions EBS Stock Holding History

nVerses Capital’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,500	Closed	-$12.5K	–	263
2024 Q3	$12.5K	Sell	1,500 -1,100	-42%	-$10K	0.01%	867
2024 Q2	$17.7K	Buy	+2,600	New	+$11.2K	0.01%	818

Other funds holding EBS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OHA

Oak Hill Advisors New York $878M AUM 106.46% 1-Year Est. Return

nVerses Capital's EBS Position: Q4 2024 in Review

nVerses Capital sold out of Emergent Biosolutions (EBS) in Q4 2024, closing a stake of 1,500 shares — an estimated $12.5K sold.

nVerses Capital first reported a position in EBS in Q2 2024 and held it in 2 quarters. The position peaked at $17.7K in Q2 2024. 156 funds tracked by Wall St. Rank hold EBS as of Q4 2024.

nVerses Capital reported no remaining Emergent Biosolutions position as of Q4 2024 after selling out during the quarter.
nVerses Capital sold 1,500 Emergent Biosolutions shares in Q4 2024, an estimated $12.5K.
nVerses Capital first reported a position in Emergent Biosolutions in Q2 2024 and held it in 2 quarters.
nVerses Capital's Emergent Biosolutions position peaked at $17.7K in Q2 2024.
156 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.